Sign inJoin waitlistJoin the waitlist

Katherine Tarlock

Program Director · University of Washington School of Medicine

Credentials: · ·

History

University of Washington School of Medicine
Present
University of Washington School of Medicine Fellowship
Present
High Risk Leukemia Program · University of Washington School of Medicine
Present

Pediatric Hematology/Oncology
University of Washington School of Medicine
2011–2014
Pediatrics
Stanford Health Care
2008–2011
Doctor of Medicine
2004–2008

Research

Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy
Blood · 2019 · 238 citations
Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio FLT3/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol…
Journal of Clinical Oncology · 2022 · 98 citations
CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group
Blood · 2021 · First of 18 authors · 87 citations

Soheil Meshinchi
30 papers · 5 as a fellow
Todd Cooper
18 papers
EK
Edward Kolb
14 papers
Richard Aplenc
14 papers
Alan Gamis
13 papers
Jessica Pollard
9 papers
Benjamin Huang
6 papers
Danielle Kirkey
5 papers · 2 as a fellow
Scott Furlan
5 papers
Ann Dahlberg
4 papers
Keith Loeb
4 papers
Paul Carpenter
4 papers

Clinical trials

FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia
Principal investigator · Recruiting · Phase 1
Fred Hutchinson Cancer Center
2025–2042
Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Principal investigator · Completed · Phase 1
National Cancer Institute (NCI)
2019–2023